Cleveland BioLabs
Cleveland BioLabs is a clinical-stage biotechnology company, founded in 2003 and headquartered in Buffalo, United States, that develops a pipeline of drug candidates for medical and defense applications. The company is no longer listed on NASDAQ and operates without disclosed commercial revenue.
- Company typePrivate
- Founded2003
- HeadquartersBuffalo, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cleveland BioLabs does
Cleveland BioLabs is a clinical-stage biotechnology company founded in 2003 and headquartered in Buffalo, United States, with a headcount of 51–100 employees. The company develops a pipeline of drug candidates targeted at multiple medical and defense applications, including indications relevant to biodefense and radiation countermeasure scenarios. Its leadership combines scientific co-founders (Michael Fonstein, Andrei Gudkov) with operational executives, currently operating under a dual-president structure with Mike Handley as President and CEO and Langdon Miller as President and CMO, supported by a CFO (Peter Aronstam) and COO (Taunia Markvicka).
The company's underlying technology and product portfolio details are not disclosed in the available data, but the company is characterized as having a robust pipeline spanning both civilian medical and military/defense use cases, suggesting dual-use development with potential go-to-market through both FDA-regulated commercial pathways and government procurement channels. Across its history, Cleveland BioLabs has executed 12 documented funding rounds totaling roughly $111 million from 2003 through February 2021, with investors including Hercules Capital and Norma Investment, alongside undisclosed equity backers.
Cleveland BioLabs is no longer publicly listed (delisted from NASDAQ under ticker CBLI) and shows no documented revenue, consistent with its clinical-stage status. Its business model is therefore capital-raise driven rather than commercial-revenue driven, with monetization likely contingent on future licensing agreements, government procurement contracts, or product approvals that have not materialized in the available data. The company has not completed a documented financing round since February 2021, indicating constrained access to capital relative to its earlier pace of one to two raises per year.
Cleveland BioLabs firmographics
Firmographics- Name
- Cleveland BioLabs
- Website
- https://cbiolabs.com
- Company type
- Private
- Founded year
- 2003
- Headcount range
- 51–100 employees
- Short description
- Cleveland BioLabs is a clinical-stage biotechnology company, founded in 2003 and headquartered in Buffalo, United States, that develops a pipeline of drug candidates for medical and defense applications. The company is no longer listed on NASDAQ and operates without disclosed commercial revenue.
- Ownership category
- akta.pro rank
Cleveland BioLabs industry classification
Industry- Product category
- Clinical-stage Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
- akta.pro secondary industries
- Biothreat/Biocontainment & Select Agent Public Health Laboratories (HLAJAIAL), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Cleveland BioLabs is headquartered
LocationHeadquarters
- HQ city
- Buffalo
- HQ country
- United States
- HQ region
- North America
Markets served
Cleveland BioLabs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Cleveland BioLabs product offering
Product offeringCore offering
Cleveland BioLabs is a clinical-stage biotech company developing a pipeline of drug candidates aimed at multiple medical and defense applications. The company's offerings center on proprietary pharmaceutical compounds advancing through preclinical and clinical development stages, with therapeutic focus areas spanning tissue damage, oncology, and radioprotection. No specific product names are disclosed in the source input.
Differentiator
Problem solved
Functional benefit
Companies that use Cleveland BioLabs
Customer profileIdeal customer profiles2 records
Cleveland BioLabs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cleveland BioLabs partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Cleveland BioLabs competitors and assessment
Company assessmentBroad incumbents
- Emergent BioSolutions: Emergent is a large, established biodefense and specialty pharma company with a broad portfolio of FDA-approved medical countermeasures (anthrax, smallpox, botulism) and government contracts — the same end-market Cleveland BioLabs targets, but at much greater scale.
- Bavarian Nordic: Bavarian Nordic is a fully-integrated biodefense vaccine company with approved smallpox and Ebola vaccines sold to governments worldwide, comparable to CBLI as a biodefense countermeasure developer with a more mature, broader commercial portfolio.
- BioCryst Pharmaceuticals: BioCryst is a clinical-stage to commercial rare-disease and infectious-disease biotech with government countermeasure collaborations (e.g., oral antiviral programs), reflecting the same mix of government-funded and commercial pipeline development that CBLI pursues.
- Novavax: Novavax is a clinical-to-commercial vaccine company that has historically pursued both pandemic/seasonal and biodefense vaccine opportunities, comparable to CBLI's dual-use biologic platform approach though at far greater scale.
Direct peers
- Diffusion Pharmaceuticals: Diffusion Pharmaceuticals develops trans-sodium crocetinate (TSC) for radiation-induced tissue injury and oncology supportive care, directly overlapping CBLI's entolimod radiation-countermeasure and oncology-supportive-care indications.
- Humanetics Corporation: Humanetics is the direct corporate successor for entolimod/BPR0P-004 (formerly partnered with CBLI's joint venture) and develops radiation countermeasures and TBI mitigators, making it the closest clinical-stage comparable in the same therapeutic niche.
- Soligenix: Soligenix is a clinical-stage biodefense and rare-disease biotech with active development of medical countermeasures (e.g., ricin and anthrax vaccines, SGX942), mirroring Cleveland BioLabs' combination of biodefense programs and small-molecule clinical assets.
- SIGA Technologies: SIGA commercializes TPOXX, a biodefense countermeasure for smallpox, and derives the majority of its revenue from government stockpiling contracts — the same government-procurement revenue model Cleveland BioLabs is pursuing with entolimod.
Emerging players
- Altimmune: Altimmune is an emerging clinical-stage biotech developing vaccines and immunotherapeutics, including biodefense-adjacent programs, providing a comparable smaller-cap dual-use platform story for Cleveland BioLabs.
- Tonix Pharmaceuticals: Tonix is an emerging clinical-stage pharma with a diversified pipeline spanning CNS, immunology, and biodefense (e.g., TNX-801 horsepox-based vaccine), making it a comparable small-cap multi-program biotech with government countermeasure exposure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Cleveland BioLabs social profiles
Digital presenceCleveland BioLabs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cleveland BioLabs leadership team
Management profileNumber of profiles
Profiles7 records
Cleveland BioLabs funding detail
Funding detailFunding overview
Funding rounds12 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cleveland BioLabs M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cleveland BioLabs
What does Cleveland BioLabs do?
Cleveland BioLabs is a clinical-stage biotech company developing a pipeline of drug candidates aimed at multiple medical and defense applications. The company's offerings center on proprietary pharmaceutical compounds advancing through preclinical and clinical development stages, with therapeutic focus areas spanning tissue damage, oncology, and radioprotection. No specific product names are disclosed in the source input.
When was Cleveland BioLabs founded?
Cleveland BioLabs was founded in 2003. It employs 51 to 100 people.
Where is Cleveland BioLabs based?
Cleveland BioLabs is headquartered in Buffalo, United States, in the North America region.
Who are Cleveland BioLabs's main competitors?
Broad incumbents on record are Emergent BioSolutions, Bavarian Nordic, BioCryst Pharmaceuticals and Novavax. Direct peers are Diffusion Pharmaceuticals, Humanetics Corporation, Soligenix and SIGA Technologies. Emerging players are Altimmune and Tonix Pharmaceuticals.
Does Cleveland BioLabs have an API?
No public API is recorded for Cleveland BioLabs.
What industry is Cleveland BioLabs in?
Cleveland BioLabs's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAJAIAL, Biothreat/Biocontainment & Select Agent Public Health Laboratories. Its NAICS code is 541714 and its SIC code is 2836.